Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tavapadon Phase 2 in PD Motor Fluctuations
NCT02687542Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Mar 2016
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of tavapadon in Parkinson's disease (PD) (5 arms), sponsored by Pfizer. Primary endpoint: Change From Baseline in Daily OFF Time at 10 weeks. Started Mar 2016; status: terminated.
02
Drugs
tavapadon
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02687542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02687542.